000241139 001__ 241139
000241139 005__ 20240229154915.0
000241139 0247_ $$2doi$$a10.1002/ctm2.1186
000241139 0247_ $$2pmid$$apmid:36718025
000241139 0247_ $$2altmetric$$aaltmetric:141975965
000241139 037__ $$aDKFZ-2023-00252
000241139 041__ $$aEnglish
000241139 082__ $$a610
000241139 1001_ $$0P:(DE-He78)c6c6ce72f4dff102e38d74f7143a2ea8$$aPane, Antonino$$b0$$eFirst author$$udkfz
000241139 245__ $$aMicroRNAs affecting the susceptibility of melanoma cells to CD8+ T cell-mediated cytolysis.
000241139 260__ $$aHoboken, NJ$$bWiley$$c2023
000241139 3367_ $$2DRIVER$$aarticle
000241139 3367_ $$2DataCite$$aOutput Types/Journal article
000241139 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1675332547_2340
000241139 3367_ $$2BibTeX$$aARTICLE
000241139 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000241139 3367_ $$00$$2EndNote$$aJournal Article
000241139 500__ $$a#EA:D210#LA:D210#
000241139 520__ $$aThe regulatory functions of microRNAs (miRNAs) in anti-tumour immunity have been mainly described in immune effector cells. Since little is known about miRNA effects on the susceptibility of target cells during T cell-target cell interaction, this study focused on the identification of miRNAs expressed in tumour cells controlling their susceptibility to CD8+ T cell-mediated cytotoxicity.Luciferase expressing B16F10 melanoma (B16F10 Luci+ ) cells transfected with individual miRNAs covering a comprehensive murine miRNA library were screened for their susceptibility to lysis by an established cytotoxic T lymphocyte (CTL) line (5a, clone Nβ) specific for the melanoma-associated antigen tyrosinase-related protein 2. miRNAs with the most pronounced effects on T cell-mediated lysis were validated and stably expressed in B16F10 cells. In silico analyses identified common targets of miRNA sets determined by the screen, which were further confirmed by small interfering RNA (siRNA)-mediated silencing experiments modulating immune surveillance. The Ingenuity Pathway Analysis (IPA) software and RNA sequencing (RNA-seq) data from miRNA-overexpressing cell lines were applied to investigate the underlying mechanisms. The Cancer Genome Atlas (TCGA)-derived miRNA sequencing data were used to assess the correlation of miRNA expression with melanoma patients' survival.The miRNA screen resulted in the selection of seven miRNAs enhancing CTL-mediated melanoma cell killing in vitro. Upon stable overexpression of selected miRNAs, hsa-miR-320a-3p, mmu-miR-7037-5p and mmu-miR-666-3p were determined as most effective in enhancing susceptibility to CTL lysis. In silico analyses and subsequent siRNA-mediated silencing experiments identified Psmc3 and Ndufa1 as common miRNA targets possibly involved in the functional effects observed. The analyses of RNA-seq data with IPA showed pathways, networks, biological functions and key molecules potentially involved in the miRNA-mediated functional effects. Finally, based on TCGA data analysis, a positive correlation of the conserved miRNAs among the panel of the seven identified miRNAs with overall survival of melanoma patients was determined.For the first time, this study uncovered miRNA species that affect the susceptibility of melanoma cells to T cell-mediated killing. These miRNAs might represent attractive candidates for novel therapy approaches against melanoma and other tumour entities.
000241139 536__ $$0G:(DE-HGF)POF4-314$$a314 - Immunologie und Krebs (POF4-314)$$cPOF4-314$$fPOF IV$$x0
000241139 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000241139 650_7 $$2Other$$aNdufa1
000241139 650_7 $$2Other$$aPsmc3
000241139 650_7 $$2Other$$acytotoxic T lymphocyte (CTL)
000241139 650_7 $$2Other$$amelanoma
000241139 650_7 $$2Other$$amiRNA
000241139 650_7 $$2Other$$ascreening
000241139 650_7 $$2NLM Chemicals$$aMicroRNAs
000241139 650_7 $$2NLM Chemicals$$aRNA, Small Interfering
000241139 650_2 $$2MeSH$$aHumans
000241139 650_2 $$2MeSH$$aAnimals
000241139 650_2 $$2MeSH$$aMice
000241139 650_2 $$2MeSH$$aMicroRNAs: genetics
000241139 650_2 $$2MeSH$$aMicroRNAs: metabolism
000241139 650_2 $$2MeSH$$aMelanoma: genetics
000241139 650_2 $$2MeSH$$aRNA, Small Interfering
000241139 650_2 $$2MeSH$$aCD8-Positive T-Lymphocytes: metabolism
000241139 7001_ $$0P:(DE-He78)70e630b77e8ddc41353fc23197569b7c$$aKordaß, Theresa$$b1$$udkfz
000241139 7001_ $$0P:(DE-He78)2f34b89d62d5e5c651aa1e683844b092$$aHotz-Wagenblatt, Agnes$$b2$$udkfz
000241139 7001_ $$0P:(DE-He78)eed71877972a029b8b099222b2ddbe0d$$aDickes, Elke$$b3$$udkfz
000241139 7001_ $$0P:(DE-He78)bb6a7a70f976eb8df1769944bf913596$$aKopp-Schneider, Annette$$b4$$udkfz
000241139 7001_ $$0P:(DE-He78)18218139eec55d83cf82679934e5cd75$$aWill, Rainer$$b5$$udkfz
000241139 7001_ $$00000-0002-5544-4958$$aSeliger, Barbara$$b6
000241139 7001_ $$0P:(DE-He78)b757b21d60bbaa4164899bb7e61b0c15$$aOsen, Wolfram$$b7$$udkfz
000241139 7001_ $$0P:(DE-He78)23fb8cfffbf2aa8eee5d51af417ad944$$aEichmüller, Stefan$$b8$$eLast author$$udkfz
000241139 773__ $$0PERI:(DE-600)2697013-2$$a10.1002/ctm2.1186$$gVol. 13, no. 2$$n2$$pe1186$$tClinical and translational medicine$$v13$$x2001-1326$$y2023
000241139 909CO $$ooai:inrepo02.dkfz.de:241139$$pVDB
000241139 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)c6c6ce72f4dff102e38d74f7143a2ea8$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000241139 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)70e630b77e8ddc41353fc23197569b7c$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000241139 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)2f34b89d62d5e5c651aa1e683844b092$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000241139 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)eed71877972a029b8b099222b2ddbe0d$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000241139 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)bb6a7a70f976eb8df1769944bf913596$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000241139 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)18218139eec55d83cf82679934e5cd75$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000241139 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)b757b21d60bbaa4164899bb7e61b0c15$$aDeutsches Krebsforschungszentrum$$b7$$kDKFZ
000241139 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)23fb8cfffbf2aa8eee5d51af417ad944$$aDeutsches Krebsforschungszentrum$$b8$$kDKFZ
000241139 9131_ $$0G:(DE-HGF)POF4-314$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vImmunologie und Krebs$$x0
000241139 9141_ $$y2023
000241139 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2020-06-08T15:16:46Z
000241139 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2020-06-08T15:16:46Z
000241139 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ$$d2020-06-08T15:16:46Z
000241139 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2022-11-09
000241139 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2022-11-09
000241139 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2022-11-09
000241139 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2022-11-09
000241139 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bCLIN TRANSL MED : 2022$$d2023-10-26
000241139 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-10-26
000241139 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-10-26
000241139 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2023-10-26
000241139 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Anonymous peer review$$d2020-06-08T15:16:46Z
000241139 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2023-10-26
000241139 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2023-10-26
000241139 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-10-26
000241139 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-10-26
000241139 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2023-10-26
000241139 915__ $$0StatID:(DE-HGF)9910$$2StatID$$aIF >= 10$$bCLIN TRANSL MED : 2022$$d2023-10-26
000241139 9202_ $$0I:(DE-He78)D210-20160331$$kD210$$lGMP-Einheit Zelluläre Therapie$$x0
000241139 9201_ $$0I:(DE-He78)D210-20160331$$kD210$$lGMP-Einheit Zelluläre Therapie$$x0
000241139 9201_ $$0I:(DE-He78)W610-20160331$$kW610$$lW610 Core Facility Omics IT$$x1
000241139 9201_ $$0I:(DE-He78)C060-20160331$$kC060$$lC060 Biostatistik$$x2
000241139 9201_ $$0I:(DE-He78)W111-20160331$$kW111$$lZelluläre Tools$$x3
000241139 9200_ $$0I:(DE-He78)D210-20160331$$kD210$$lGMP-Einheit Zelluläre Therapie$$x0
000241139 980__ $$ajournal
000241139 980__ $$aVDB
000241139 980__ $$aI:(DE-He78)D210-20160331
000241139 980__ $$aI:(DE-He78)W610-20160331
000241139 980__ $$aI:(DE-He78)C060-20160331
000241139 980__ $$aI:(DE-He78)W111-20160331
000241139 980__ $$aUNRESTRICTED